Evaluate Eribulin ORA in Subjects With Solid Tumors


Study Number
74818
Phase
I
Purpose

This is a nonrandomized, open-label, dosed escalation, safety activity, and PK study to determine the MTD and optimal dosing regimen of Eribulin ORA.

Full Title

A Phase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA (HM30181A + Eribulin) in Subjects with Solid Tumors

ClinicalTrials.Gov ID
NCT04013217

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.